| [1] |
Kaplan D, Casper TC, Elliott CG, et al. VTE incidence and risk factors in patients with severe sepsis and septic shock[J]. Chest, 2015, 148(5):1224-1230.
|
| [2] |
Li L, Zhou J, Huang L, et al. Prevention, treatment, and risk factors of deep vein thrombosis in critically ill patients in Zhejiang province, China: A multicenter, prospective, observational study[J]. Ann Med, 2021, 53(1):2234-2245.
|
| [3] |
Minet C, Potton L, Bonadona A, et al. Venous thromboembolism in the ICU: Main characteristics, diagnosis and thromboprophylaxis[J]. Crit Care, 2015, 19(1):287.
|
| [4] |
Boonyawat K, Crowther MA. Venous thromboembolism prophylaxis in critically ill patients[J]. Semin Thromb Hemost, 2015, 41(1):68-74.
|
| [5] |
Spencer FA, Gurwitz JH, Schulman S, et al. Venous thromboembolism in older adults: A community-based study[J]. Am J Med, 2014, 127(6):530-537.e3.
|
| [6] |
Tritschler T, Aujesky D. Venous thromboembolism in the elderly: A narrative review[J]. Thromb Res, 2017, 155:140-147.
|
| [7] |
ISTH Steering Committee for World Thrombosis Day. Thrombosis: A major contributor to global disease burden[J]. Thromb Res, 2014, 134(5):931-938.
|
| [8] |
Casciano JP, Dotiwala Z, Kemp R, et al. Economic burden of recurrent venous thromboembolism: Analysis from a U.S. hospital perspective[J]. Am J Health Syst Pharm, 2015, 72(4):291-300.
|
| [9] |
Yan J, Zhou J, Zhen J, et al. Knowledge and awareness of venous thromboembolism in intensive care units in Zhejiang province, China: A cross-sectional survey[J/OL]. Med Sci Monit, 2020, 26:e923378.
|
| [10] |
Darzi AJ, Repp AB, Spencer FA, et al. Risk-assessment models for VTE and bleeding in hospitalized medical patients: An overview of systematic reviews[J]. Blood Adv, 2020, 4(19):4929-4944.
|
| [11] |
Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141(2 Suppl):e195S-e226S.
|
| [12] |
Obi AT, Pannucci CJ, Nackashi A, et al. Validation of the caprini venous thromboembolism risk assessment model in critically ill surgical patients[J]. JAMA Surg, 2015, 150(10):941-948.
|
| [13] |
Li L, Zhen J, Huang L, et al. The risk factors for deep venous thrombosis in critically ill older adult patients: A subgroup analysis of a prospective, multicenter, observational study[J]. BMC Geriatr, 2022, 22(1):977.
|
| [14] |
Chen X, Huang J, Liu J, et al. Venous thromboembolism risk factors and prophylaxis of elderly intensive care unit patients in a Chinese general hospital[J]. Ann Palliat Med, 2021, 10(4):4453-4462.
|
| [15] |
Chen X, Pan L, Deng H, et al. Risk assessment in Chinese hospitalized patients comparing the padua and caprini scoring algorithms[J]. Clin Appl Thromb Hemost, 2018, 24(9_suppl):127S-135S.
|
| [16] |
Cook D, Crowther M, Meade M, et al. Deep venous thrombosis in medical-surgical critically ill patients: Prevalence, incidence, and risk factors[J]. Crit Care Med, 2005, 33(7):1565-1571.
|
| [17] |
Viarasilpa T, Panyavachiraporn N, Marashi SM, et al. Prediction of symptomatic venous thromboembolism in critically ill patients: The ICU-venous thromboembolism score[J/OL]. Crit Care Med, 2020, 48(6):e470-e479.
|
| [18] |
Mei R, Wang G, Chen R, et al. The ICU-venous thromboembolism score and tumor grade can predict inhospital venous thromboembolism occurrence in critical patients with tumors[J]. World J Surg Oncol, 2022, 20(1):245.
|
| [19] |
Ryan L, Mataraso S, Siefkas A, et al. A machine learning approach to predict deep venous thrombosis among hospitalized patients[J]. Clin Appl Thromb Hemost, 2021, 27:1076029621991185.
|
| [20] |
Ho KM, Chavan S, Pilcher D. Omission of early thromboprophylaxis and mortality in critically ill patients: A multicenter registry study[J]. Chest, 2011, 140(6):1436-1446.
|
| [21] |
邱贵兴.中国骨科大手术静脉血栓栓塞症预防指南[J/CD].中华关节外科杂志（电子版），2009，3(3):380-383.
|
| [22] |
Haase C, Joergensen M, Ellervik C, et al. Age- and sex-dependent reference intervals for D-dimer: Evidence for a marked increase by age[J]. Thromb Res, 2013, 132(6):676-680.
|
| [23] |
De Pooter N, Brionne-François M, Smahi M, et al. Age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in patients with non-high pre-test probability: Clinical performance and cost-effectiveness analysis[J]. J Thromb Haemost, 2021, 19(5):1271-1282.
|
| [24] |
Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: The ADJUST-PE study[J]. JAMA, 2014, 311(11):1117-1124.
|
| [25] |
Jaconelli T, Eragat M, Crane S. Can an age-adjusted D-dimer level be adopted in managing venous thromboembolism in the emergency department? A retrospective cohort study[J]. Eur J Emerg Med, 2018, 25(4):288-294.
|
| [26] |
Schouten HJ, Geersing GJ, Koek HL, et al. Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: Systematic review and meta-analysis[J]. BMJ, 2013, 346:f2492.
|
| [27] |
Robinson KS, Anderson DR, Gross M, et al. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: The post-arthroplasty screening study. A randomized, controlled trial[J]. Ann Intern Med, 1997, 127(6):439-445.
|
| [28] |
Furlan JC, Fehlings MG. Role of screening tests for deep venous thrombosis in asymptomatic adults with acute spinal cord injury: An evidence-based analysis[J]. Spine (Phila Pa 1976), 2007, 32(17):1908-1916.
|
| [29] |
Allen CJ, Murray CR, Meizoso JP, et al. Surveillance and early management of deep vein thrombosis decreases rate of pulmonary embolism in high-risk trauma patients[J]. J Am Coll Surg, 2016, 222(1):65-72.
|
| [30] |
Arabi YM, Burns K, Alsolamy SJ, et al. Surveillance or no surveillance ultrasonography for deep vein thrombosis and outcomes of critically ill patients: A pre-planned sub-study of the PREVENT trial[J]. Intensive Care Med, 2020, 46(4):737-746.
|
| [31] |
Kory PD, Pellecchia CM, Shiloh AL, et al. Accuracy of ultrasonography performed by critical care physicians for the diagnosis of DVT[J]. Chest, 2011, 139(3):538-542.
|
| [32] |
Roberts L, Rozen T, Murphy D, et al. A preliminary study of intensivist-performed DVT ultrasound screening in trauma ICU patients (APSIT Study)[J]. Ann Intensive Care, 2020, 10(1):122.
|
| [33] |
Hamper UM, DeJong MR, Scoutt LM. Ultrasound evaluation of the lower extremity veins[J]. Radiol Clin North Am, 2007, 45(3):525-547.
|
| [34] |
Boddi M, Peris A. Deep vein thrombosis in intensive care[J]. Adv Exp Med Biol, 2017, 906:167-181.
|
| [35] |
Boddi M, Barbani F, Abbate R, et al. Reduction in deep vein thrombosis incidence in intensive care after a clinician education program[J]. J Thromb Haemost, 2010, 8(1):121-128.
|
| [36] |
肺血栓栓塞症-深静脉血栓形成影像学检查操作规程(推荐方案)[J].中华结核和呼吸杂志，2005，28(9):580-589.
|
| [37] |
Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients: Findings from the IMPROVE investigators[J]. Chest, 2011, 139(1):69-79.
|
| [38] |
中华医学会重症医学分会. ICU病人深静脉血栓形成预防指南[J].中国实用外科杂志，2009，29(10):793-797.
|
| [39] |
Morawski W, Sanak M, Cisowski M, et al. Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: Role of aspirin and platelet glycoprotein IIIa polymorphism[J]. J Thorac Cardiovasc Surg, 2005, 130(3):791-796.
|
| [40] |
Kang W, Theman TE, Reed JF, et al. The effect of preoperative clopidogrel on bleeding after coronary artery bypass surgery[J]. J Surg Educ, 2007, 64(2):88-92.
|
| [41] |
Karthik S, Grayson AD, McCarron EE, et al. Reexploration for bleeding after coronary artery bypass surgery: Risk factors, outcomes, and the effect of time delay[J]. Ann Thorac Surg, 2004, 78(2):527-534.
|
| [42] |
Detterbeck FC, Rivera MP, Socinski M. Diagnosis and treatment of lung cancer: An evidence-based guide for the practicing clinician[M]. Philadelphia, PA: WB Saunders, 2001:133-147.
|
| [43] |
Danish SF, Burnett MG, Ong JG, et al. Prophylaxis for deep venous thrombosis in craniotomy patients: A decision analysis[J]. Neurosurgery, 2005, 56(6):1286-1292.
|
| [44] |
Hemmila MR, Jakubus JL, Maggio PM, et al. Real money: Complications and hospital costs in trauma patients[J]. Surgery, 2008, 144(2):307-316.
|
| [45] |
Rocha AT, de Vasconcellos AG, da Luz Neto ER, et al. Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery[J]. Obes Surg, 2006, 16(12):1645-1655.
|
| [46] |
Sima CS, Jarnagin WR, Fong Y, et al. Predicting the risk of perioperative transfusion for patients undergoing elective hepatectomy[J]. Ann Surg, 2009, 250(6):914-921.
|
| [47] |
Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group[J]. Lancet, 1993, 341(8840):259-265.
|
| [48] |
Reynolds MW, Clark J, Crean S, et al. Risk of bleeding in surgical patients treated with topical bovine thrombin sealants: A review of the literature[J]. Patient Saf Surg, 2008, 2:5.
|
| [49] |
Tung EC, Yu SY, Shah K, et al. Reassessment of venous thromboembolism and bleeding risk in medical patients receiving VTE prophylaxis[J]. J Eval Clin Pract, 2020, 26(1):18-25.
|
| [50] |
Cade JF. High risk of the critically ill for venous thromboembolism[J]. Crit Care Med, 1982, 10(7):448-450.
|
| [51] |
Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France[J]. Am J Respir Crit Care Med, 2000, 161(4 Pt 1):1109-1114.
|
| [52] |
Gaitanidis A, Breen KA, Christensen MA, et al. Low-molecular weight heparin is superior to unfractionated heparin for elderly trauma patients[J]. J Surg Res, 2021, 268:432-439.
|
| [53] |
De A, Roy P, Garg VK, et al. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery[J]. Blood Coagul Fibrinolysis, 2010, 21(1):57-61.
|
| [54] |
Shen L, Qiu L, Liu D, et al. The association of low molecular weight heparin use and in-hospital mortality among patients hospitalized with COVID-19[J]. Cardiovasc Drugs Ther, 2022, 36(1):113-120.
|
| [55] |
Cook D, Meade M, Guyatt G, et al. Dalteparin versus unfractionated heparin in critically ill patients[J]. N Engl J Med, 2011, 364(14):1305-1314.
|
| [56] |
Fernando SM, Tran A, Cheng W, et al. VTE prophylaxis in critically ill adults: A systematic review and network meta-analysis[J]. Chest, 2022, 161(2):418-428.
|
| [57] |
Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: Prophylaxis for hospitalized and nonhospitalized medical patients[J]. Blood Adv, 2018, 2(22):3198-3225.
|
| [58] |
Duranteau J, Taccone FS, Verhamme P, et al. European guidelines on perioperative venous thromboembolism prophylaxis: Intensive care[J]. Eur J Anaesthesiol, 2018, 35(2):142-146.
|
| [59] |
Park D, Southern W, Calvo M, et al. Treatment with dalteparin is associated with a lower risk of bleeding compared to treatment with unfractionated heparin in patients with renal insufficiency[J]. J Gen Intern Med, 2016, 31(2):182-187.
|
| [60] |
Pai M, Adhikari N, Ostermann M, et al. Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial[J/OL]. PLoS One, 2018, 13(6):e0198285.
|
| [61] |
Sebaaly J, Covert K. Enoxaparin dosing at extremes of weight: Literature review and dosing recommendations[J]. Ann Pharmacother, 2018, 52(9):898-909.
|
| [62] |
Bickford A, Majercik S, Bledsoe J, et al. Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient[J]. Am J Surg, 2013, 206(6):847-851.
|
| [63] |
Wang TF, Milligan PE, Wong CA, et al. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients[J]. Thromb Haemost, 2014, 111(1):88-93.
|
| [64] |
Freeman A, Horner T, Pendleton RC, et al. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity[J]. Am J Hematol, 2012, 87(7):740-743.
|
| [65] |
Miranda S, Le Cam-Duchez V, Benichou J, et al. Adjusted value of thromboprophylaxis in hospitalized obese patients: A comparative study of two regimens of enoxaparin: The ITOHENOX study[J]. Thromb Res, 2017, 155:1-5.
|
| [66] |
Rojas L, Aizman A, Ernst D, et al. Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms[J]. Thromb Res, 2013, 132(6):761-764.
|
| [67] |
Ebeid A, Cole E, Stallwood-Hall C. The efficacy of weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients: A systematic review and meta-analysis[J]. J Trauma Acute Care Surg, 2022, 93(2):e71-e79.
|
| [68] |
Robinson S, Zincuk A, Larsen UL, et al. A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: A double-blinded, randomised controlled trial[J]. Crit Care, 2013, 17(2):R75.
|
| [69] |
Acharya P, Upadhyay L, Qavi A, et al. The paradox prevails: Outcomes are better in critically ill obese patients regardless of the comorbidity burden[J]. J Crit Care, 2019, 53:25-31.
|
| [70] |
Keller K, Engelhardt M. Strength and muscle mass loss with aging process. Age and strength loss[J]. Muscles Ligaments Tendons J, 2013, 3(4):346-350.
|
| [71] |
Rosenthal MD, Kamel AY, Rosenthal CM, et al. Chronic critical illness: Application of what we know[J]. Nutr Clin Pract, 2018, 33(1):39-45.
|
| [72] |
Singla DL, Morrill GB. Warfarin maintenance dosages in the very elderly[J]. Am J Health Syst Pharm, 2005, 62(10):1062-1066.
|
| [73] |
The use of oral anticoagulants (warfarin) in older people. American Geriatrics Society guideline[J]. J Am Geriatr Soc, 2002, 50(8):1439-1445.
|
| [74] |
Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism[J]. N Engl J Med, 2009, 361(24):2342-2352.
|
| [75] |
Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis[J]. Circulation, 2014, 129(7):764-772.
|
| [76] |
Büller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism[J]. N Engl J Med, 2012, 366(14):1287-1297.
|
| [77] |
Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism[J]. N Engl J Med, 2010, 363(26):2499-2510.
|
| [78] |
Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism[J]. N Engl J Med, 2013, 369(9):799-808.
|
| [79] |
Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism[J]. N Engl J Med, 2013, 369(15):1406-1415.
|
| [80] |
Kubitza D, Becka M, Roth A, et al. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor[J]. J Clin Pharmacol, 2013, 53(3):249-255.
|
| [81] |
Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor[J]. Br J Clin Pharmacol, 2010,70(5):703-712.
|
| [82] |
中华医学会外科学分会血管外科学组.深静脉血栓形成的诊断和治疗指南（第三版）[J]. 中华血管外科杂志，2017，2(4):201-208.
|
| [83] |
中华医学会外科学分会.中国普通外科围手术期血栓预防与管理指南[J].中华外科杂志，2016，54(5):321-327.
|
| [84] |
《老年人心房颤动诊治中国专家建议》写作组，中华医学会老年医学分会，中华老年医学杂志编辑委员会.老年人非瓣膜性心房颤动诊治中国专家建议(2016)[J].中华老年医学杂志，2016，35(9):915-928.
|
| [85] |
Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety[J]. Chest, 2001, 119(1 Suppl):64S-94S.
|
| [86] |
Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, et al. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group[J]. Thromb Haemost, 1994, 71(6):698-702.
|
| [87] |
Sachdeva A, Dalton M, Lees T. Graduated compression stockings for prevention of deep vein thrombosis[J]. Cochrane Database Syst Rev, 2018, 11(11):CD001484.
|
| [88] |
Morris RJ, Woodcock JP. Intermittent pneumatic compression or graduated compression stockings for deep vein thrombosis prophylaxis? A systematic review of direct clinical comparisons[J]. Ann Surg, 2010, 251(3):393-396.
|
| [89] |
Ho KM, Tan JA. Stratified meta-analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients[J]. Circulation, 2013, 128(9):1003-1020.
|
| [90] |
Arabi YM, Khedr M, Dara SI, et al. Use of intermittent pneumatic compression and not graduated compression stockings is associated with lower incident VTE in critically ill patients: A multiple propensity scores adjusted analysis[J]. Chest, 2013, 144(1):152-159.
|
| [91] |
Elliott CG, Dudney TM, Egger M, et al. Calf-thigh sequential pneumatic compression compared with plantar venous pneumatic compression to prevent deep-vein thrombosis after non-lower extremity trauma[J]. J Trauma, 1999, 47(1):25-32.
|
| [92] |
Fujisawa M, Naito M, Asayama I, et al. Effect of calf-thigh intermittent pneumatic compression device after total hip arthroplasty: Comparative analysis with plantar compression on the effectiveness of reducing thrombogenesis and leg swelling[J]. J Orthop Sci, 2003, 8(6):807-811.
|
| [93] |
|
| [94] |
Proctor MC, Greenfield LJ, Wakefield TW, et al. A clinical comparison of pneumatic compression devices: the basis for selection[J]. J Vasc Surg, 2001, 34(3):459-463.
|
| [95] |
Arabi YM, Al-Hameed F, Burns K, et al. Adjunctive intermittent pneumatic compression for venous thromboprophylaxis[J]. N Engl J Med, 2019, 380(14):1305-1315.
|
| [96] |
Fan C, Jia L, Fang F, et al. Adjunctive intermittent pneumatic compression in hospitalized patients receiving pharmacologic prophylaxis for venous thromboprophylaxis: A systematic review and meta-analysis[J]. J Nurs Scholarsh, 2020, 52(4):397-405.
|
| [97] |
Rappold JF, Sheppard FR, Carmichael Ii SP, et al. Venous thromboembolism prophylaxis in the trauma intensive care unit: An American Association for the Surgery of Trauma Critical Care Committee clinical consensus document[J/OL]. Trauma Surg Acute Care Open, 2021, 6(1):e000643.
|
| [98] |
Castagna L, Maggioni E, Coppo A, et al. Safe ECMO femoral decannulation by placement of inferior vena cava filter via internal jugular vein[J]. J Artif Organs, 2016, 19(3):297-300.
|
| [99] |
Bikdeli B, Chatterjee S, Desai NR, et al. Inferior vena cava filters to prevent pulmonary embolism: Systematic review and meta-analysis[J]. J Am Coll Cardiol, 2017, 70(13):1587-1597.
|
| [100] |
Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report [J]. Chest, 2021, 160(6):e545-e608.
|
| [101] |
中华医学会外科学分会血管外科学组，中国医师协会血管外科医师分会，海峡两岸医药卫生交流协会血管外科分会，等.孤立性远端深静脉血栓诊疗建议[J].中华普通外科杂志，2021，36(9):719-721.
|
| [102] |
Rajasekhar A, Streiff MB. How I treat central venous access device-related upper extremity deep vein thrombosis[J]. Blood, 2017, 129(20):2727-2736.
|
| [103] |
Monreal M, Alastrue A, Rull M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin)[J]. Thromb Haemost, 1996, 75(2):251-253.
|
| [104] |
Verso M, Agnelli G, Bertoglio S, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: A double-blind, placebo-controlled, randomized study in cancer patients[J]. J Clin Oncol, 2005, 23(18):4057-4062.
|
| [105] |
Karthaus M, Kretzschmar A, Kröning H, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: Final results of a double-blind, placebo-controlled phase III trial[J]. Ann Oncol, 2006, 17(2):289-296.
|
| [106] |
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report[J]. Chest, 2016, 149(2):315-352.
|
| [107] |
Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer[J]. Blood Adv, 2021, 5(4):927-974.
|
| [108] |
Davies GA, Lazo-Langner A, Gandara E, et al. A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2)[J]. Thromb Res, 2018, 162:88-92.
|
| [109] |
Schiffer CA, Mangu PB, Wade JC, et al. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2013, 31(10):1357-1370.
|